Ofatumumab (Arzerra 100 mg or 1000 mg concentrate for solution for infusion) is indicated for the treatment of untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL).

ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia (CLL) (1): in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate.

2024年12月9日 · Arzerra is used to treat chronic lymphocytic leukemia (CLL), usually in combination with other medicines, such as chlorambucil, or with fludarabine and cyclophosphamide for those with relapsed CLL. Arzerra is given as an intravenous infusion.

Arzerra（ofatumumab）奥法木单抗 ， 是一种人源化靶向抗CD20单克隆抗体，通过与B细胞表面的CD20结合，达到从血液循环中清除B细胞的效果。 2009年被FDA批准用于治疗慢性淋巴细胞白血病（CLL），以品牌名Arzerra销售。 Kesimpta（ofatumumab）奥法木单抗 ， OMBI157， 是首个可通过Sensoready自动注射笔让患者在家中每月自我注射1次的B细胞靶向疗法，用于治疗多发性硬化症（MS），以品牌名Kesimpta销售。

ARZERRATM (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab....

2024年6月26日 · ARZERRA (ofatumumab) is a sterile, clear to opalescent, colorless, preservative-free liquid concentrate (20 mg/mL) for dilution and intravenous administration provided in single-use glass vials ...

Arzerra (ofatumumab) is in a class of drugs called anti-CD20-directed monoclonal antibodies. It is used to treat chronic lymphocytic leukemia (CLL) in patients who have further disease after...

Arzerra is indicated for the treatment of CLL in adult patients who are refractory to fludarabine and alemtuzumab. See section 5.1 for further information. Arzerra should be administered under the supervision of a physician experienced in the use of cancer therapy and in an environment where full resuscitation facilities are immediately available.

奥法妥木单抗（Ofatumumab）于2009年首次被美国FDA批准用于治疗慢性淋巴细胞性白血病（CLL）患者，商品名为Arzerra，通过高剂量静脉输注给药（不同于上述剂型）。

Arzerra（ofatumumab）是一种全人源化单克隆抗体，靶向CLL细胞和正常B淋巴细胞表面的CD20分子。 在美国，Arzerra已获批联合苯丁酸氮芥（chlorambucil）用于不适合氟达拉滨治疗的初治CLL患者。